DIIs place big bets on 2 pharma giants. Multibaggers in the making?

While foreign investors have been reducing their exposure to Indian pharma, some leading domestic institutional investors (DIIs) are doing exactly the opposite. Two pharmaceutical giants have recently caught their attention, with them seeing about 4% jump in DII Holding in the last quarter alone. What do these institutional powerhouses see that others might be missing?